Novant Health Initiates Phase 2 COVID-19 Trial with CytoDyn’s Leronlimab
VANCOUVER, Washington and WINSTON-SALEM, N.C., April 07, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for …